Iaso Therapeutics, based in East Lansing, MI, is a dedicated biotech company focused on developing next-generation vaccines to enhance human health and combat diseases. With a particular emphasis on newly emerged pathogens, Iaso Therapeutics aims to utilize novel technologies, such as their disruptive virus-like particle mutant Q platform, to create effective vaccines that generate superior antibodies compared to traditional carrier proteins.
Recognized for their potential, Iaso Therapeutics has been included on the Renaissance Venture Capital Spring 2023 Startup Hotlist, showcasing their promise as one of the most promising early-stage companies in the Midwest. Additionally, the company recently closed the first tranche of their $1.25M Series Seed Preferred round of financing, further solidifying their commitment to advancing innovative vaccine technologies.
Generated from the website